# Veeva Systems Type: Company (VEEV) Source: GetYourBrief — https://getyourbrief.com/entity/veeva-systems Canonical HTML page: https://getyourbrief.com/entity/veeva-systems ## Timeline - **2030-01-01**: Revenue Milestone Target — Target date for achieving a $6 billion annual revenue run rate. - **2026-03-08**: Analyst Target Cuts — TD Cowen and Canaccord Genuity slash price targets citing competitive risks and valuation. - **2026-03-05**: Market Volatility — VEEV stock surges 11% on long-term outlook before retreating on disclosure concerns. - **2026-03-04**: Q4 Earnings Report — Veeva reports advancing income and sets a $6B revenue target for 2030. - **2026-03-04**: Competitive Disclosure — Management reveals competitive losses in the CRM segment during the earnings call. - **2025-03-05**: Strategic Migration — Veeva accelerates the transition of customers from Salesforce-based CRM to proprietary Vault CRM. - **2025**: Market Maturity — Revenue reaches $3.2B TTM as the company targets a $20B total addressable market. - **2024-03-04**: Q4 Earnings Growth — Company reports advancing income and robust demand for Vault platform. - **2020**: Vault Expansion — The company aggressively expands its Vault platform into clinical, quality, and regulatory sectors. - **2013-10-16**: Initial Public Offering — Veeva Systems goes public, establishing itself as a leader in life sciences CRM. - **2013-10-16**: IPO Launch — Veeva Systems goes public, establishing the vertical SaaS model for life sciences. ## Recent coverage (16 stories, network-wide) ### AppLovin Plunges 9.2% After Fed Shock—What AdTech Investors Must Know 2026-08-04 19:06:39 · Sector: marketing · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Shares of mobile ad platform AppLovin tumbled 9.2% alongside other software names after the Federal Reserve signaled no 2026 rate cuts. The sell-off highlights adtech’s acute sensitivity to interest rates, but AppLovin’s AI-driven programmatic model and high volatility may present a trading opportunity for marketing professionals attuned to macro swings. Full story: https://getmarketingbrief.com/story/applovin-fed-selloff-adtech-2026 ### Veeva Systems Drops 5.3% in Tech Sell-Off—A Buying Opportunity for Pharma SaaS? 2026-08-04 19:06:32 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Veeva Systems (VEEV) fell 5.3% to $201.56 during a broader software rout triggered by the Federal Reserve’s hawkish dot plot. The life-sciences cloud leader faces the same rate-driven multiple compression as other SaaS names, but its pharma client base and mission-critical R&D applications may insulate revenue, creating a potential long-term entry point for biotech investors. Full story: https://getbiobrief.com/story/veeva-systems-fed-selloff-biotech-2026 ### SaaS Stocks Surge as AI Rotation Fuels 4.3% ServiceNow Gain 2026-07-20 14:04:43 · Sector: saas · Sentiment: Positive · Impact: 6/10 · Sources: 1 Investors rotated from chips to oversold enterprise software on July 13, 2026, sending SaaS stocks higher. ServiceNow jumped 4.3% and Salesforce rose 2.4%, powered by renewed confidence in AI monetization after the SaaSpocalypse. The shift signals a new phase where application-layer SaaS becomes the AI control point. Full story: https://getsaasbrief.com/story/saas-stocks-surge-ai-rotation ### Datatrak and TAILRD Heart Partner to Scale AI in Clinical Research 2026-03-16 23:55:51 · Sector: saas · Sentiment: Positive · Impact: 6/10 · Sources: 3 Datatrak and TAILRD Heart have announced a strategic collaboration to integrate advanced AI capabilities into life sciences clinical research. The partnership aims to modernize data collection and analysis, accelerating the development of healthcare treatments through cloud-based innovation. Full story: https://getsaasbrief.com/story/datatrak-tailrd-heart-ai-clinical-research-collaboration ### Veeva Systems: Can the Life Sciences Cloud Leader Create Multimillionaires? 2026-03-15 00:39:59 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Veeva Systems remains a dominant force in the life sciences cloud sector, boasting a 13.6% CAGR since its 2013 IPO and a client list including 15 of the top 20 biopharma firms. While revenue growth is moderating as the company matures, its $20 billion total addressable market and high switching costs suggest significant long-term compounding potential. Full story: https://getfinancebrief.com/story/veeva-systems-investment-analysis-2026 ### Veeva Systems: Scaling Toward $6B Revenue Amid Life Sciences Dominance 2026-03-15 00:39:21 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Veeva Systems remains a cornerstone of the life sciences cloud, targeting a $6 billion revenue run rate by 2030. Despite recent competitive pressures and a strategic migration to its proprietary Vault CRM, the company’s deep integration with 15 of the top 20 biopharma firms provides a robust long-term growth foundation. Full story: https://getsaasbrief.com/story/veeva-systems-life-sciences-cloud-analysis ### Veeva Systems: Analyzing the Long-Term Growth Potential in Life Sciences Cloud 2026-03-15 00:37:48 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Veeva Systems maintains a dominant position in the life sciences cloud market, serving 15 of the top 20 biopharma firms. While revenue growth has moderated to $3.2 billion, the company's $20 billion total addressable market and high switching costs position it as a resilient long-term play. Full story: https://gethealthbrief.com/story/veeva-systems-growth-analysis-life-sciences-cloud ### Analysts Recalibrate Veeva Systems Outlook Amid Vault CRM Migration 2026-03-08 13:44:57 · Sector: saas · Sentiment: Neutral · Impact: 5/10 · Sources: 2 TD Cowen and Canaccord Genuity Group have significantly lowered their price targets for Veeva Systems (VEEV) following a complex quarterly update. While the company maintains a bullish long-term revenue outlook, analysts are increasingly focused on execution risks surrounding its proprietary CRM migration and recent competitive pressures. Full story: https://getsaasbrief.com/story/veeva-systems-price-target-cuts-analysis-2026 ### Veeva Systems Faces Valuation Pressure as Analysts Slash Price Targets 2026-03-08 13:43:23 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Veeva Systems (VEEV) is navigating a complex post-earnings landscape as major analysts, including TD Cowen and Canaccord Genuity, significantly lower their price targets. Despite a bullish long-term revenue outlook, recent management disclosures regarding competitive losses have triggered a wave of valuation adjustments across Wall Street. Full story: https://getfinancebrief.com/story/veeva-systems-analyst-price-target-cuts-march-2026 ### Analysts Slash Veeva Systems Price Targets Amid Vault CRM Migration Risks 2026-03-08 13:42:50 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2 Veeva Systems is facing a wave of price target reductions from major analysts, including TD Cowen and Canaccord Genuity, reflecting caution over its platform transition. While management maintains a $6 billion revenue target for 2030, recent disclosures of competitive losses have tempered market enthusiasm. Full story: https://gethealthbrief.com/story/veeva-systems-price-target-cuts-analysis ### AI-Driven Growth: Top Stock Picks for the 2026 Machine Learning Expansion 2026-03-04 04:14:08 · Sector: ai · Sentiment: Positive · Impact: 6/10 · Sources: 2 As the AI sector matures in 2026, investors are pivoting toward companies that successfully integrate generative AI and machine learning into specialized verticals like healthcare and voice automation. Key players including Eli Lilly and SoundHound AI are demonstrating how AI-powered drug discovery and conversational interfaces are translating into significant revenue growth and market leadership. Full story: https://getaibrief.com/story/ai-growth-stocks-2026-analysis ### AI and Specialized Cloud Infrastructure Drive 2026 Growth Stock Outlook 2026-03-04 04:13:05 · Sector: saas · Sentiment: Positive · Impact: 6/10 · Sources: 2 As market volatility persists in early 2026, analysts are identifying high-conviction growth opportunities in AI-integrated healthcare and specialized cloud infrastructure. Companies like Nebius and SoundHound AI are demonstrating explosive revenue trajectories, while Veeva Systems continues to dominate the vertical SaaS landscape for life sciences. Full story: https://getsaasbrief.com/story/ai-cloud-growth-stocks-2026-analysis ### Growth Stock Outlook 2026: AI, Biotech, and Infrastructure Lead H1 Picks 2026-03-04 04:12:31 · Sector: startups · Sentiment: Positive · Impact: 6/10 · Sources: 2 As market volatility persists in early 2026, analysts are pivoting toward high-conviction growth plays in healthcare AI and specialized compute infrastructure. Key picks include Eli Lilly's pharmaceutical dominance and Nebius's explosive ARR projections, signaling a shift toward companies with proven revenue scaling. Full story: https://getstartupbrief.com/story/growth-stock-outlook-2026-ai-biotech-infrastructure ### Growth Stock Outlook 2026: Pharma Giants and AI Disruptors Lead Market 2026-03-04 04:11:57 · Sector: finance · Sentiment: Positive · Impact: 6/10 · Sources: 2 As equity markets navigate 2026 volatility, analysts are highlighting a mix of established healthcare leaders and emerging AI infrastructure plays as top growth opportunities. Eli Lilly’s dominance in the obesity market and Nebius’s projected $7 billion revenue surge represent the diverse strategies for capturing alpha in the current cycle. Full story: https://getfinancebrief.com/story/growth-stocks-outlook-h1-2026 ### Eli Lilly and Veeva Lead 2026 Growth Outlook Amid AI-Driven Pharma Shift 2026-03-04 04:11:43 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2 As market volatility persists in early 2026, Eli Lilly and Veeva Systems emerge as top growth picks driven by the obesity drug boom and AI integration. With Eli Lilly's tirzepatide securing its spot as the world's top-selling drug and new oral GLP-1s on the horizon, the pharmaceutical landscape is shifting toward tech-heavy, high-margin innovation. Full story: https://getbiobrief.com/story/eli-lilly-veeva-2026-growth-outlook ### Pharma Giants and AI Disruptors: Top Healthcare Growth Stocks for 2026 2026-03-04 04:09:39 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2 Eli Lilly and Veeva Systems emerge as dominant healthcare growth leaders for 2026, driven by the GLP-1 weight-loss revolution and cloud-based life sciences infrastructure. Meanwhile, SoundHound AI is positioning itself to disrupt medical administrative costs through generative voice AI and automated customer service solutions. Full story: https://gethealthbrief.com/story/healthcare-growth-stocks-2026-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.